Commitment
Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Tozaride, our lead product entering Phase 2 clinical trials, targets specific cancers at the molecular level, and its companion diagnostic identifies the patients with the corresponding molecular signature who are the best candidates for therapy.
News & Events
Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at international lung cancer meeting
Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA —January 8, 2018— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of…
Read MoreA Billion Dollar Drug Using a Virtual Business Model
Chris Adams, CEO, Andarix, explains how industry can leverage technology to make the drug development process more efficient In the drug development world, coming up with a billion-dollar drug is almost like winning the lottery, except that there is a lot of hard work, false leads, and significant technical and financial risk. This article discusses the…
Read MoreAndarix Pharmaceuticals Selected to Present at Lung Cancer Summit in Boston, MA
Targeted Tozaride Drug Therapy is effective for Small Cell Lung Cancer SOMERVILLE, Mass.— July 24, 2017 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017.…
Read More